{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:24:11Z","timestamp":1793363051537,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>Antibody-mediated rejection (AMR) is among the most frequent causes for graft loss after kidney transplantation. While there are no approved therapies, several case reports with daratumumab and the very recent phase 2 trial of felzartamab in AMR have indicated the potential efficacy of therapeutic interventions targeting CD38. Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker with injury-specific release and a short half-life, which could facilitate early diagnosis of AMR and monitoring of treatment response. We describe two cases of patients with chronic active AMR, who were treated with monthly daratumumab infusions, and in whom donor-derived cell-free DNA (dd-cfDNA) was measured longitudinally to monitor treatment response. In both patients, daratumumab treatment led to stabilization of kidney function parameters, a strong decline of dd-cfDNA below the previously established threshold for rejection, and partial or complete histologic resolution of AMR activity. Our case series suggests that dd-cfDNA may be a useful companion biomarker for longitudinal monitoring of anti-CD38 treatment in patients with AMR.<\/jats:p>","DOI":"10.3389\/ti.2024.13213","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:26:04Z","timestamp":1722489964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series"],"prefix":"10.3389","volume":"37","author":[{"given":"Bilgin","family":"Osmanodja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Akifova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Bornemann-Kolatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian Malte","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kowald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.2020081215","article-title":"Exploring the Complexity of Death-Censored Kidney Allograft Failure","volume":"32","author":"Mayrdorfer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/tri.13436","article-title":"The Therapeutic challenge of Late Antibody-Mediated Kidney Allograft Rejection","volume":"32","author":"B\u00f6hmig","year":"2019","journal-title":"Transpl Int"},{"key":"B3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended Treatment for Antibody-Mediated Rejection after Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of Chronic Antibody Mediated Rejection With Intravenous Immunoglobulins and Rituximab: A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transpl"},{"key":"B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transpl"},{"key":"B7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s Monoclonal Antibody BIVV009 in Late Antibody-Mediated Kidney Allograft Rejection-Results From a First-In-Patient Phase 1 Trial","volume":"18","author":"Eskandary","year":"2018","journal-title":"Am J Transpl"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/TP.0000000000003247","article-title":"CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-Mediated Kidney Allograft Rejection","volume":"105","author":"Doberer","year":"2021","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.ajt.2023.06.018","article-title":"Daratumumab for Antibody-Mediated Rejection: Is It Time to Target the Real Culprit?","volume":"23","author":"de Nattes","year":"2023","journal-title":"Am J Transpl"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1087597","DOI":"10.3389\/fimmu.2022.1087597","article-title":"Case Report: Daratumumab for Treatment of Refractory Late or Chronic Active Antibody-Mediated Rejection in Renal Allograft Recipients With High Levels of De Novo Donor-Specific Antibodies","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ajt.2023.12.005","article-title":"Natural Killer Cell Functional Genetics and Donor-Specific Antibody-Triggered Microvascular Inflammation","volume":"13","author":"Diebold","year":"2023","journal-title":"Am J Transpl"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1031894","DOI":"10.3389\/fgene.2022.1031894","article-title":"Donor-Derived Cell-Free DNA as a Diagnostic Tool in Transplantation","volume":"13","author":"Oellerich","year":"2022","journal-title":"Front Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1182\/blood-2021-152068","article-title":"Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM)","volume":"138","author":"Burns","year":"2021","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1111\/ajt.15416","article-title":"Absolute Quantification of Donor-Derived Cell-Free DNA as a Marker of Rejection and Graft Injury in Kidney Transplantation: Results From a Prospective Observational Study","volume":"19","author":"Oellerich","year":"2019","journal-title":"Am J Transpl"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1373\/clinchem.2013.210328","article-title":"Digital Droplet PCR for Rapid Quantification of Donor DNA in the Circulation of Transplant Recipients as a Potential Universal Biomarker of Graft Injury","volume":"59","author":"Beck","year":"2013","journal-title":"Clin Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.kint.2022.09.030","article-title":"A Banff-Based Histologic Chronicity Index Is Associated With Graft Loss in Patients With a Kidney Transplant and Antibody-Mediated Rejection","volume":"103","author":"Haas","year":"2023","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T-Cell Expansion, and Skews T-Cell Repertoire in Multiple Myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous Versus Intravenous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (COLUMBA): A Multicentre, Open-Label, Non-Inferiority, Randomised, Phase 3 Trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1038\/s41467-019-13113-5","article-title":"Missing Self Triggers NK Cell-Mediated Chronic Vascular Rejection of Solid Organ Transplants","volume":"10","author":"Koenig","year":"2019","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000538513","article-title":"Successful Desensitization With Imlifidase and Daratumumab in a Highly Immunized, Crossmatch Positive, Blood Group-Incompatible Living-Donor Re-Transplant Recipient With Systemic Lupus Erythematosus and Antiphospholipid Syndrome","volume":"51","author":"Schrezenmeier","year":"2024","journal-title":"Transfus Med Hemother"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.13213\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:26:08Z","timestamp":1722489968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.13213\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":23,"alternative-id":["10.3389\/ti.2024.13213"],"URL":"https:\/\/doi.org\/10.3389\/ti.2024.13213","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"article-number":"13213"}}